Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15853672 | 1.00 | CYP1A2 (0.42) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| Hydrochloric Acid SCHEMBL29856334 | 0.98 | CYP1A2 (0.41) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| SCHEMBL23514429 | 0.93 | HSD17B10 (0.40) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| Hydrochloric Acid SCHEMBL23499905 | 0.92 | HSD17B10 (0.39) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| SCHEMBL15853678 | 0.82 | DPP7 (0.41) | — | |
| SCHEMBL15853681 | 0.81 | DPP7 (0.43) | — | |
| SCHEMBL30484009 | 0.81 | HTR1A (0.46) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| SCHEMBL8975358 | 0.81 | DPP7 (0.43) | — | |
| SCHEMBL16197319 | 0.81 | CYP1A2 (0.45) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| SCHEMBL14843166 | 0.81 | CYP1A2 (0.45) | CYP1A2TDP1HSD17B10CHRM1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024477-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024477-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | CTH, CBS, SLC6A12 | CYP1A2 1516/4885TDP1 2891/4885HSD17B10 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.